法国赛诺菲喜保宁是什么药？

(Vigabatrin tablets) is the first new anti-epileptic drug developed and designed based on the pathophysiological mechanism of the disease. Based on the understanding of the relationship between the GABA neurotransmitter system and the onset of epilepsy, scientists have synthesized vigabatrin, which has a chemical structure very similar to the natural neurotransmitter GABA. The intention is to make this compound compete with GABA, inhibit GABA aminotransferase, delay the metabolism of GABA, increase GABAergic neurotransmission and its mediated neural inhibition, and achieve the effect of inhibiting epileptic seizures.

France's Sanofi Vigabatrin is indicated for: infantile spasms (IS) in infants aged 1 month to 2 years old; together with other therapies, it is used to treat refractory complex partial-onset epilepsy (CPS) in adults and children aged 10 years and above. As a chemical structural analog of the natural neurotransmitter γ-aminobutyric acid (GABA), Vigabatrin inhibits the metabolism of GABA by competing with GABA for GABA aminotransferase and increases the central nervous system inhibitory effect of the GABAergic neurotransmitter system.

Clinical pharmacology studies have found that the half-life of vigabatrin in the human body is only 5 to 7 hours, and its content in cerebrospinal fluid is only 10% of the circulating exposure. Despite this, after a single dose of Vigabatrin, the GABA content in the brain increased 5 times compared with no administration, and this could be maintained for nearly 1 week. This suggests that the effect of Vigabatrin on GABA aminotransferase may be an irreversible covalent binding inhibition. After inhibition occurs, the activity of GABA aminotransferase can return to normal only through enzyme synthesis and renewal, which also provides a basis for the frequency of clinical administration of Vigabatrin (once a day).

Sanofi is one of the first multinational pharmaceutical groups to open offices in China and is one of the fastest growing pharmaceutical and health companies in China. Currently, Sanofi has more than 6,000 employees in more than 200 cities in China, and its products have been launched abroad, providing another new choice for patient treatment.

Recommended hot articles: /newsDetail/93709.html